Drug Discovery News and Research

RSS

The drug discovery process begins with recognizing a disease or clinical condition in which there is a lack of adequate medical treatment. Once a potential drug has been identified, pre-clinical research can begin. This process includes several stages; the first of which involves identifying and validating the prospective drug’s target through assay development, high throughput screening, hit identification and finally, lead optimization. Once the pre-clinical process is complete, the newly synthesized drug candidate is selected for future clinical development.

Brain Science Institute, Eisai sign licensing agreement to develop GCPII inhibitors

Johns Hopkins University's newly formed Brain Science Institute's NeuroTranslational Program has entered into a licensing agreement with pharmaceutical company Eisai Inc. to discover and develop small molecule glutamate carboxypeptidase II (GCPII) inhibitors.

15 Mar 2010

UVA, Merck collaborate to discover novel drugs for women's reproductive health

The University of Virginia in Charlottesville today announced that it has entered into a research collaboration with Merck (known as MSD outside the United States and Canada) to discover novel drugs for women's reproductive health.

12 Mar 2010

BeaconEquity.com announces investment report featuring NexMed

BeaconEquity.com announces an investment report featuring NexMed Inc. (Nasdaq:NEXM). The report includes financial, comparative and investment analyses, and industry information you need to know to make an educated investment decision.

12 Mar 2010

TechniScan utilizes NVIDIA Tesla GPUs in WBU system for diagnostic breast imaging

TechniScan, Inc. is featured on NVIDIA's recently posted blog about speeding the amount of time it takes to get breast imaging results into the hands of doctors and patients. NVIDIA is the world leader in visual computing technologies and inventor of the graphics processing unit.

12 Mar 2010

StemCells reports net loss of $5.23M for fourth-quarter fiscal 2009

StemCells, Inc. today reported financial results for the fourth quarter and year ended December 31, 2009. The Company's results include the operations of Stem Cell Sciences Plc (SCS) since April 1, 2009.

11 Mar 2010

Data from novel Hedgehog pathway inhibitor program to be presented at upcoming conferences

Infinity Pharmaceuticals, Inc., an innovative drug discovery and development company, today announced that members of its senior leadership and scientific teams will be leading discussions and presenting data from its novel Hedgehog pathway inhibitor program – an emerging area of cancer research – at several upcoming conferences.

11 Mar 2010

Ampicillin activates torsinA, improves cell function to reduce movement disorders

Discovery of an antibiotic's capacity to improve cell function in laboratory tests is providing movement disorder researchers with leads to more desirable molecules with potentially similar traits, according to University of Alabama scientists co-authoring a paper publishing March 10 in the journal Disease Models & Mechanisms.

11 Mar 2010

Lowering levels of Coonexin46 with use of siRNA will help prevent tumor formation

What began as research into how diabetics could possibly preserve their eyesight has led to findings that could prolong the vision of children afflicted with retinoblastoma.

10 Mar 2010

Lonza acquires access to PCA technology patent portfolio

Odyssey Thera, Inc., announced today the signing of an agreement with Lonza to make Odyssey Thera's proprietary Protein-fragment Complementation Assay (PCA) technology, as part of compound profiling services, available to life science and drug discovery researchers.

10 Mar 2010

Novel protein haditoxin in King Cobra's venom discovered

The King Cobra continues to weave its charm with researchers identifying a protein in its venom with the potential for new drug discovery and to advance understanding of disease mechanisms.

9 Mar 2010

Restructuring results in reduction of Exelixis’ workforce by 40% and increases financial strength

Exelixis, Inc. today announced a restructuring as a consequence of its continued strategy to focus resources on the development of its key late-stage compounds. As its first priority, the company will aggressively advance XL184, XL147 and XL765, each of which is the subject of a large clinical development program.

9 Mar 2010

RepRegen's Strontium-based bioactive glass platform encourages osteoblast cell activity and proliferation

RepRegen™, the ‘smart biomaterials’ company previously known as BioCeramic Therapeutics, announced today that data from an in vitro study has demonstrated that its patented Strontium-based bioactive glass platform promotes osteoblast cell activity and proliferation. If in vivo studies, which are currently underway, demonstrate similar results, then RepRegen believes its platform has the potential to significantly improve the repair and regeneration of hard-tissue, such as bone.

9 Mar 2010

Three researchers to be honored with SBS Award for achievement in biomolecular sciences and lead discovery

The Society for Biomolecular Sciences will honor three researchers for their substantial contributions to the field of drug discovery. Each recipient will accept their award and speak at the SBS 16th Annual Conference & Exhibition in Phoenix, Arizona, April 11-15, 2010.

9 Mar 2010

Entelos, RegeneMed release iToxFX to screen novel compounds for potential toxicity issues

Entelos, Inc., a simulation and modeling company focused on human health, and RegeneMed, Inc., a tissue-based drug discovery and regenerative medicine company, announced today the release of iToxFX™.

8 Mar 2010

Sigma Life Science extends portfolio of knockout rat models with the release of ADME/Tox applications

Sigma® Life Science, an innovative brand of Sigma-Aldrich®, today extended its portfolio of knockout rat models with the announcement of a new suite of models designed to facilitate more predictive absorption, distribution, metabolism, excretion and toxicity (ADME/Tox) studies.

8 Mar 2010

Roche, OrbiMed, McKinsey announce fifteen finalists of SEED Competition

Roche, OrbiMed, and McKinsey announced fifteen finalists of the SEED Competition at the SEED Finalist Coaching Day event in Shanghai’s Zhangjiang Hi-Tech Park on March 2, 2010. The event was managed and presented by ChinaBio® Accelerator. The finalists will go on to compete for the grand prize of RMB 300,000 to be presented at the SEED Final Competition and Award Ceremony in Shanghai on April 23, 2010.

6 Mar 2010

LEO Pharma gains access to Intomics’ biological data analysis expertises

Today, Intomics A/S and LEO Pharma A/S announced a collaboration under which LEO Pharma gains access to Intomics’ unique biological data analysis expertises. The recently founded spin-off company from The Danish Technical University, Intomics, has methods and tools for use in LEO Pharma’s early drug discovery.

5 Mar 2010

Chay Enterprises merges with DMI Life Sciences to form Ampio Pharmaceuticals

Chay Enterprises, Inc. is pleased to announce today that the company has merged with DMI Life Sciences, Inc to form Ampio Pharmaceuticals, Inc. Ampio Pharmaceuticals will trade on the NASDAQ BB under the symbol CHYE. "We have asked FINRA to change our symbol," said Don Wingerter, Ampio Pharmaceuticals' CEO, "and expect to be trading under our new symbol in less than thirty days."

4 Mar 2010

AB SCIEX collaborates with Mass Spectrometry Centre to improve drug discovery and development

AB SCIEX, a global leader in life science analytical technologies, today announced that it is collaborating with the University of Geneva’s Mass Spectrometry Centre to create new workflows and analytical strategies intended to significantly improve drug discovery and development.

4 Mar 2010

Inspire Pharmaceuticals reports net loss of $2.6 million for 2009 fourth quarter

Inspire Pharmaceuticals, Inc. announced today financial results for the fourth quarter and year ended December 31, 2009, reporting a net loss of $2.6 million or ($0.03) per share for the fourth quarter and a net loss of $40.0 million or ($0.60) per share for the full year.

4 Mar 2010

Drug Discovery News and Research

Further Reading

Brain Science Institute, Eisai sign licensing agreement to develop GCPII inhibitors

UVA, Merck collaborate to discover novel drugs for women's reproductive health

BeaconEquity.com announces investment report featuring NexMed

TechniScan utilizes NVIDIA Tesla GPUs in WBU system for diagnostic breast imaging

StemCells reports net loss of $5.23M for fourth-quarter fiscal 2009

Data from novel Hedgehog pathway inhibitor program to be presented at upcoming conferences

Ampicillin activates torsinA, improves cell function to reduce movement disorders

Lowering levels of Coonexin46 with use of siRNA will help prevent tumor formation

Lonza acquires access to PCA technology patent portfolio

Novel protein haditoxin in King Cobra's venom discovered

Restructuring results in reduction of Exelixis’ workforce by 40% and increases financial strength

RepRegen's Strontium-based bioactive glass platform encourages osteoblast cell activity and proliferation

Three researchers to be honored with SBS Award for achievement in biomolecular sciences and lead discovery

Entelos, RegeneMed release iToxFX to screen novel compounds for potential toxicity issues

Sigma Life Science extends portfolio of knockout rat models with the release of ADME/Tox applications

Roche, OrbiMed, McKinsey announce fifteen finalists of SEED Competition

LEO Pharma gains access to Intomics’ biological data analysis expertises

Chay Enterprises merges with DMI Life Sciences to form Ampio Pharmaceuticals

AB SCIEX collaborates with Mass Spectrometry Centre to improve drug discovery and development

Inspire Pharmaceuticals reports net loss of $2.6 million for 2009 fourth quarter

Drug Discovery - Second Edition eBook

Expanding research and clinical options for children with cancer

Examining how pain could play a direct protective role in the gut

From Puberty to Menopause: Clue’s CEO, Audrey Tsang on the Power of Femtech

Latest Life Science News